Metagenomi (MGX) CFO Pamela Wapnick Sells 1,911 Shares

What Happened
Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics, sold 1,911 shares of common stock on 2026-09-08 at $1.16 per share, generating proceeds of $2,214. The transaction is a sale (S) and was executed to cover tax withholding obligations tied to vested restricted stock units, not an independent decision to liquidate holdings.

Key Details

• Transaction date: 2026-09-08; Form 4 filed: 2026-09-10 (timely filing).
• Price and quantity: 1,911 shares at $1.16 per share; total proceeds $2,214.
• Transaction code: S (Sale). Footnote F1: shares were automatically sold to satisfy tax withholding on RSUs granted 4/1/2024 and 4/1/2025 — not a volitional trade.
• Shares owned after the transaction: not disclosed in the provided filing.
• Filing timeliness: filed within the standard reporting window; not marked late.

Context
This was an automatic, tax-withholding sale tied to RSU vesting (a routine corporate administration action). Such forced sell-to-cover transactions are common and generally carry less informational weight about an insider’s view of the company than discretionary open-market purchases or larger sales. The dollar amount here is very small ($2.2k), so it’s unlikely to indicate a change in insider sentiment.